Curated News
By: NewsRamp Editorial Staff
July 15, 2025
Kairos Pharma Reports Positive Phase 2 Trial Results for Prostate Cancer Therapy
TLDR
- Kairos Pharma's ENV-105 shows promising safety in Phase 2 trials, positioning it as a potential leader in cancer therapy with a competitive edge in the biopharma sector.
- Kairos Pharma's Phase 2 trial of ENV-105 demonstrates no dose-limiting toxicities, combining well with apalutamide, indicating a methodical approach to overcoming cancer drug resistance.
- ENV-105's progress in clinical trials offers hope for better prostate cancer treatments, aiming to improve patient outcomes and quality of life globally.
- Discover how Kairos Pharma's innovative ENV-105 targets CD105 to reverse drug resistance, a breakthrough in the fight against metastatic castration-resistant prostate cancer.
Impact - Why it Matters
This news is significant for patients with metastatic castration-resistant prostate cancer, a condition with limited treatment options. The favorable safety profile of ENV-105, combined with its potential to overcome drug resistance, offers hope for more effective therapies. For the medical community and investors, Kairos Pharma's progress represents a promising advancement in oncology therapeutics, potentially leading to breakthroughs in treating not just prostate cancer but other resistant cancers as well.
Summary
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced promising interim safety results from its Phase 2 trial of ENV-105 (carotuximab) for metastatic castration-resistant prostate cancer. The trial, involving the first-in-class CD105 antagonist, reported no dose-limiting toxicities or unexpected adverse events in the initial ten patients, with ENV-105 being well tolerated alongside standard hormone therapy apalutamide. Conducted at prestigious centers including Cedars-Sinai and City of Hope, the study anticipates interim efficacy data by September 2025, with Kairos preparing for discussions on a potential Phase 3 study with regulators.
Kairos Pharma, based in Los Angeles, is pioneering in oncology therapeutics, focusing on overcoming drug resistance and immune suppression in cancer through structural biology. ENV-105, its lead candidate, targets CD105, a protein linked to resistance in various cancer treatments, aiming to restore the efficacy of standard therapies across multiple cancer types. The company's innovative approach addresses significant unmet needs in cancer treatment, with ongoing trials for prostate and lung cancers. For more details, visit Kairos Pharma and www.KairosPharma.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma Reports Positive Phase 2 Trial Results for Prostate Cancer Therapy
